CSIMarket
 
Bard C R Inc  (BCR)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 75
 Employees 13,900
 Revenues (TTM) (Millions $) 3,941
 Net Income (TTM) (Millions $) 817
 Cash Flow (TTM) (Millions $) -91
 Capital Exp. (TTM) (Millions $) 127

Bard C R Inc
C. R. Bard, Inc. Is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. Charles Russell Bard started the company in 1907. One of its first medical products was the silk urethral catheter imported from France. In 1923, the company was incorporated as C. R. Bard, Inc. and distributed an assortment of urology and surgical products. Bard became a publicly traded company in 1963 and five years later was traded on the New York Stock Exchange. Today, the company markets its products worldwide to hospitals, individual health care professionals, extended care facilities and alternate site facilities. In general, the company's products are intended to be used once and then discarded. Bard holds strong market positions in vascular, urology, oncology and surgical specialty products.


    Next quarterly dividend pay out on May 10, 2021.


Customers Net Income grew by BCR's customers Net margin fell to 9.51 %

6.75 %

1.13 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MDT   -3.2%    
BSX   -2.6%    
EW   -100%    
ABBV        3.47% 
ABT   -2.48%    
BMY   -2.04%    
• View Complete Report
   



Lazard Group Llc

Lazard Group Llc announced financial time frame ending Mar 31 2021 operating income of $136.393 millions

In the financial time frame ending Mar 31 2021 Lazard Group Llc reached break-even of $0.00 per share compared to $-1.50 a year ago and from $782.48 per share from the previous quarter.

Sales fell sharply by -87.48% to $679.11 millions from $5.43 billions in the same quarter a year ago and sequentially Revenue turn positive from $-10,163.04 millions.

Emmaus Life Sciences inc

Emmaus Life Sciences Inc announced financial fourth quarter of 2020 operating surplus of $8.9536 millions

Despite very strong Sales growth of 3398.35% year on year to $16.10 millions in the financial fourth quarter of 2020, company faced turn a round at $0.24.

compared to previous quarter EPS turn positive from $-0.23 per share and Sales increased by 2.65 % from $15.68 millions.
Emmaus Life Sciences Inc reported earnings of $1.10 millions and Sales of $23.17 millions for the fiscal year 2020.

Company reported earnings per share of $0.02 compared to $-1.30 in the previous fiscal year, while Sales increased by 1.82 % from $22.75 millions a year ago.

Galecto Inc

Losses Widen but Revenues Unchanged

In the fiscal time frame ending Mar 31 2021 Galecto Inc increased losses of $-0.53 per share compared to $-0.27 a year ago and eps fell from $1.07 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.46 millions in the same quarter a year ago and sequentially from $0.00 millions.

Sage Therapeutics Inc

Sage Therapeutics Inc announced first quarter of 2021 operating loss of $-96.507 millions

Declining demand caused increase in loss for the first quarter of 2021, company's loss per share grew to $-1.64 from $-2.44 where Sales fell by -30.75% to $1.58 millions from $2.29 millions a year ago.

In contrast to the fourth quarter by -99.86% from $1.11 billions and eps fell from $17.35 per share.

Kaleido Biosciences Inc

Logged a Loss but Revenues Unchanged

In the first quarter of 2021 Kaleido Biosciences Inc lost money of $-0.58 per share compared to $-0.64 a year ago and increased losses from $-0.56 per share from the previous quarter.

Sales remained unchanged to $0.30 millions from $0.00 millions in the same quarter a year ago and sequentially Sales improved by 22.22 % from $0.24 millions.






 

Bard C R Inc's Segments
 
Vascular
 Segment    28.94 % of total Revenue
Urology
 Segment    24.52 % of total Revenue
Oncology
 Segment    27.64 % of total Revenue
Surgery
 Segment    16.15 % of total Revenue
Other products
 Segment    2.75 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bard C R Inc does not provide revenue guidance.

Earnings Outlook
Kaleido Biosciences Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 68.1 %
Europe 14.7 %
Japan 4.95 %
Rest of the World 12.25 %


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

WIRE's Profile

Stock Price

WIRE's Financials

Business Description

Fundamentals

Charts & Quotes

WIRE's News

Suppliers

WIRE's Competitors

Customers & Markets

Economic Indicators

WIRE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071